Publications

  1. Asiedu GB, Eustace RW, Eton DT, Radecki Breitkopf C. Coping with colorectal cancer: a qualitative exploration with patients and their family members. Fam Pract. 2014 Jul 30.
    View PubMed
  2. May CR, Eton DT, Boehmer K, Gallacher K, Hunt K, MacDonald S, Mair FS, May CM, Montori VM, Richardson A, Rogers AE, Shippee N. Rethinking the patient: using burden of treatment theory to understand the changing dynamics of illness. BMC Health Serv Res. 2014 Jun 26; 14:281.
  3. Victorson DE, Brucker PS, Bode RK, Eton DT, Talcott JA, Clark JA, Knight SJ, Litwin MS, Moinpour CM, Reeve BB, Aaronson NK, Bennett CL, Herr HW, McGuire M, Shevrin D, McVary K, Cella D. Ensuring comprehensive assessment of urinary problems in prostate cancer through patient-physician concordance. Urol Oncol. 2014 Jan; 32(1):26.e25-31. Epub 2013 Mar 21
    View PubMed
  4. Eton DT, Beebe TJ, Hagen PT, Halyard MY, Montori VM, Naessens JM, Sloan JA, Thompson CA, Wood DL. Harmonizing and consolidating the measurement of patient-reported information at health care institutions: a position statement of the Mayo Clinic. Patient Relat Outcome Meas. 2014; 5:7-15. Epub 2014 Feb 10.
    View PubMed
  5. Domecq JP, Prutsky G, Elraiyah T, Wang Z, Nabhan M, Shippee N, Brito JP, Boehmer K, Hasan R, Firwana B, Erwin P, Eton D, Sloan J, Montori V, Asi N, Dabrh AM, Murad MH. Patient engagement in research: a systematic review. BMC Health Serv Res. 2014; 14:89. Epub 2014 Feb 26.
    View PubMed
  6. Ridgeway JL, Egginton JS, Tiedje K, Linzer M, Boehm D, Poplau S, de Oliveira DR, Odell L, Montori VM, Eton DT. Factors that lessen the burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Prefer Adherence. 2014; 8:339-51. Epub 2014 Mar 19.
    View PubMed
  7. Ridgeway JL, Beebe TJ, Chute CG, Eton DT, Hart LA, Frost MH, Jensen D, Montori VM, Smith JG, Smith SA, Tan AD, Yost KJ, Ziegenfuss JY, Sloan JA. A brief Patient-Reported Outcomes Quality of Life (PROQOL) instrument to improve patient care. PLoS Med. 2013 Nov; 10(11):e1001548. Epub 2013 Nov 12.
    View PubMed
  8. Rank MA, Ziegenfuss JY, Shah KM, Jenkins SM, Lackore KA, Eton DT, Shah ND. Is patient assessment of asthma care delivery associated with publicly reported performance measures? J Asthma. 2013 Oct; 50(8):908-14. Epub 2013 Jul 18.
    View PubMed
  9. Rank MA, Ziegenfuss JY, Shah KM, Jenkins SM, Lackore KA, Eton DT, Shah ND. Factors associated with decisions to step down asthma medications. J Allergy Clin Immunol Pract. 2013 May-Jun; 1(3):312-4. Epub 2013 Apr 09.
    View PubMed
  10. Yost KJ, Thompson CA, Eton DT, Allmer C, Ehlers SL, Habermann TM, Shanafelt TD, Maurer MJ, Slager SL, Link BK, Cerhan JR. The Functional Assessment of Cancer Therapy - General (FACT-G) is valid for monitoring quality of life in patients with non-Hodgkin lymphoma. Leuk Lymphoma. 2013 Feb; 54(2):290-7. Epub 2012 Sep 06.
    View PubMed
  11. Gallacher K, Jani B, Morrison D, Macdonald S, Blane D, Erwin P, May CR, Montori VM, Eton DT, Smith F, Batty GD, Mair FS, International Minimally Disruptive Medicine Workgroup. Qualitative systematic reviews of treatment burden in stroke, heart failure and diabetes - methodological challenges and solutions. BMC Med Res Methodol. 2013; 13:10. Epub 2013 Jan 28.
    View PubMed
  12. Eton DT, Elraiyah TA, Yost KJ, Ridgeway JL, Johnson A, Egginton JS, Mullan RJ, Murad MH, Erwin PJ, Montori VM. A systematic review of patient-reported measures of burden of treatment in three chronic diseases. Patient Relat Outcome Meas. 2013; 4:7-20. Epub 2013 Jun 05.
    View PubMed
  13. Gallacher K, Morrison D, Jani B, Macdonald S, May CR, Montori VM, Erwin PJ, Batty GD, Eton DT, Langhorne P, Mair FS. Uncovering treatment burden as a key concept for stroke care: a systematic review of qualitative research. PLoS Med. 2013; 10(6):e1001473. Epub 2013 Jun 25.
    View PubMed
  14. Suri RM, Antiel RM, Burkhart HM, Huebner M, Li Z, Eton DT, Topilsky T, Sarano ME, Schaff HV. Quality of life after early mitral valve repair using conventional and robotic approaches. Ann Thorac Surg. 2012 Mar; 93(3):761-9.
    View PubMed
  15. Eton DT, Ramalho de Oliveira D, Egginton JS, Ridgeway JL, Odell L, May CR, Montori VM. Building a measurement framework of burden of treatment in complex patients with chronic conditions: a qualitative study. Patient Relat Outcome Meas. 2012; 3:39-49. Epub 2012 Aug 24.
    View PubMed
  16. Tran VT, Montori VM, Eton DT, Baruch D, Falissard B, Ravaud P. Development and description of measurement properties of an instrument to assess treatment burden among patients with multiple chronic conditions. BMC Med. 2012; 10:68. Epub 2012 Jul 04.
    View PubMed
  17. Eton DT, Bauer BA, Sood A, Yost KJ, Sloan JA. Patient-reported outcomes in studies of complementary and alternative medicine: problems, solutions, and future directions. Explore (NY). 2011 Sep-Oct; 7(5):314-9.
    View PubMed
  18. Yost KJ, Eton DT, Garcia SF, Cella D. Minimally important differences were estimated for six Patient-Reported Outcomes Measurement Information System-Cancer scales in advanced-stage cancer patients. J Clin Epidemiol. 2011 May; 64(5):507-16.
    View PubMed
  19. Tilburt JC, James KM, Sinicrope PS, Eton DT, Costello BA, Carey J, Lane MA, Ehlers SL, Erwin PJ, Nowakowski KE, Murad MH. Factors influencing cancer risk perception in high risk populations: a systematic review. Hered Cancer Clin Pract. 2011; 9:2. Epub 2011 May 19.
    View PubMed
  20. Eton DT, Cella D. Do erythropoietic-stimulating agents relieve fatigue? A review of reviews. Cancer Treat Res. 2011; 157:181-94.
    View PubMed
  21. Eton DT, Shevrin DH, Beaumont J, Victorson D, Cella D. Constructing a conceptual framework of patient-reported outcomes for metastatic hormone-refractory prostate cancer. Value Health. 2010 Aug; 13(5):613-23. Epub 2010 Mar 10.
    View PubMed
  22. King MT, Cella D, Osoba D, Stockler M, Eton D, Thompson J, Eisenstein A. Meta-analysis provides evidence-based interpretation guidelines for the clinical significance of mean differences for the FACT-G, a cancer-specific quality of life questionnaire. Patient Relat Outcome Meas. 2010 Jul; 1:119-26. Epub 2010 Sep 23.
    View PubMed
  23. Lai JS, Bode R, Wee HL, Eton D, Cella D. A brief assessment of physical functioning for prostate cancer patients. Patient Relat Outcome Meas. 2010 Jul; 1:51-6. Epub 2010 Jun 18.
    View PubMed
  24. King MT, Stockler MR, Cella DF, Osoba D, Eton DT, Thompson J, Eisenstein AR. Meta-analysis provides evidence-based effect sizes for a cancer-specific quality-of-life questionnaire, the FACT-G. J Clin Epidemiol. 2010 Mar; 63(3):270-81. Epub 2009 Aug 27.
    View PubMed
  25. Broom R, Du H, Clemons M, Eton D, Dranitsaris G, Simmons C, Ooi W, Cella D. Switching breast cancer patients with progressive bone metastases to third-generation bisphosphonates: measuring impact using the Functional Assessment of Cancer Therapy-Bone Pain. J Pain Symptom Manage. 2009 Aug; 38(2):244-57. Epub 2009 Apr 11.
    View PubMed
  26. Cella D, Nichol MB, Eton D, Nelson JB, Mulani P. Estimating clinically meaningful changes for the Functional Assessment of Cancer Therapy--Prostate: results from a clinical trial of patients with metastatic hormone-refractory prostate cancer. Value Health. 2009 Jan-Feb; 12(1):124-9. Epub 2008 Jul 18.
    View PubMed
  27. Cella D, Eton D, Hensing TA, Masters GA, Parasuraman B. Relationship between symptom change, objective tumor measurements, and performance status during chemotherapy for advanced lung cancer. Clin Lung Cancer. 2008 Jan; 9(1):51-8.
    View PubMed
  28. Eton DT, Cella D, Yount SE, Davis KM. Validation of the functional assessment of cancer therapy--lung symptom index-12 (FLSI-12). Lung Cancer. 2007 Sep; 57(3):339-47. Epub 2007 May 07.
    View PubMed
  29. Davis K, Yount S, Del Ciello K, Whalen M, Khan S, Bass M, Du H, Eton D, Masters G, Hensing T, Cella D. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol. 2007 Sep; 5(8):381-7.
    View PubMed
  30. Burnett AL, Aus G, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus S, Liebert M, Moul JW, Tangen C, Thrasher JB, Thompson I, American Urological Association Prostate Cancer Guideline Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol. 2007 Aug; 178(2):597-601. Epub 2007 Jun 13
    View PubMed
  31. Thompson I, Thrasher JB, Aus G, Burnett AL, Canby-Hagino ED, Cookson MS, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen CM, AUA Prostate Cancer Clinical Guideline Update Panel. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
    View PubMed
  32. Cookson MS, Aus G, Burnett AL, Canby-Hagino ED, D'Amico AV, Dmochowski RR, Eton DT, Forman JD, Goldenberg SL, Hernandez J, Higano CS, Kraus SR, Moul JW, Tangen C, Thrasher JB, Thompson I. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the re porting of surgical outcomes. J Urol. 2007 Feb; 177(2):540-5.
    View PubMed
  33. Eton DT, Mendoza Temple L, Koffler K. Pilot validation of a self-report outcome measure of complementary and alternative medicine. Explore: The Journal of Science & Healing. 2007; 3:592-99.
  34. Eton DT, Yost KJ, Cella D. Future trends in patient-reported outcomes assessment for patients with advanced-stage lung cancer receiving targeted therapy. Clin Lung Cancer. 2006 Sep; 8(2):99-109.
    View PubMed
  35. Darling G, Eton DT, Sulman J, Casson AG, Celia D. Validation of the functional assessment of cancer therapy esophageal cancer subscale. Cancer. 2006 Aug 15; 107(4):854-63.
    View PubMed
  36. Helgeson VS, Lepore SJ, Eton DT. Moderators of the benefits of psychoeducational interventions for men with prostate cancer. Health Psychol. 2006 May; 25(3):348-54.
    View PubMed
  37. Steel JL, Eton DT, Cella D, Olek MC, Carr BI. Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol. 2006 Feb; 17(2):304-12. Epub 2005 Dec 15.
    View PubMed
  38. Eton DT, Cella D, Bacik J, Motzer RJ. A brief symptom index for advanced renal cell carcinoma. Health Qual Life Outcomes. 2006; 4:68. Epub 2006 Sep 26.
    View PubMed
  39. Yost KJ, Cella D, Chawla A, Holmgren E, Eton DT, Ayanian JZ, West DW. Minimally important differences were estimated for the Functional Assessment of Cancer Therapy-Colorectal (FACT-C) instrument using a combination of distribution- and anchor-based approaches. J Clin Epidemiol. 2005 Dec; 58(12):1241-51. Epub 2005 Oct 13.
    View PubMed
  40. Eton DT, Lepore SJ, Helgeson VS. Psychological distress in spouses of men treated for early-stage prostate carcinoma. Cancer. 2005 Jun 1; 103(11):2412-8.
    View PubMed
  41. Eton DT, Lai JS, Cella D, Reeve BB, Talcott JA, Clark JA, McPherson CP, Litwin MS, Moinpour CM. Data pooling and analysis to build a preliminary item bank: an example using bowel function in prostate cancer. Eval Health Prof. 2005 Jun; 28(2):142-59.
    View PubMed
  42. Yost KJ, Eton DT. Combining distribution- and anchor-based approaches to determine minimally important differences: the FACIT experience. Eval Health Prof. 2005 Jun; 28(2):172-91.
    View PubMed
  43. Eton DT, Koffler K, Cella D, Eisenstein A, Astin JA, Pelletier KR, Riley D. Developing a self-report outcome measure for complementary and alternative medicine. Explore (NY). 2005 May; 1(3):177-85.
    View PubMed
  44. Yost KJ, Yount SE, Eton DT, Silberman C, Broughton-Heyes A, Cella D. Validation of the Functional Assessment of Cancer Therapy-Breast Symptom Index (FBSI). Breast Cancer Res Treat. 2005 Apr; 90(3):295-8.
    View PubMed
  45. Butt Z, Webster K, Eisenstein AR, Beaumont J, Eton D, Masters GA, Cella D. Quality of life in lung cancer: the validity and cross-cultural applicability of the Functional Assessment Of Cancer Therapy-Lung scale. Hematol Oncol Clin North Am. 2005 Apr; 19(2):389-420, viii.
    View PubMed
  46. Eton DT, Cella D, Yost KJ, Yount SE, Peterman AH, Neuberg DS, Sledge GW, Wood WC. A combination of distribution- and anchor-based approaches determined minimally important differences (MIDs) for four endpoints in a breast cancer scale. J Clin Epidemiol. 2004 Sep; 57(9):898-910.
    View PubMed
  47. Helgeson VS, Novak SA, Lepore SJ, Eton DT. Spouse social control efforts: Relations to health behavior and well-being among men with prostate cancer. Journal of Social & Personal Relationships. 2004; 21:53-68.
  48. Lepore SJ, Helgeson VS, Eton DT, Schulz R. Improving quality of life in men with prostate cancer: a randomized controlled trial of group education interventions. Health Psychol. 2003 Sep; 22(5):443-52.
    View PubMed
  49. Eton DT, Fairclough DL, Cella D, Yount SE, Bonomi P, Johnson DH, Eastern Cooperative Oncology Group. Early change in patient-reported health during lung cancer chemotherapy predicts clinical outcomes beyond those predicted by baseline report: results from Eastern Cooperative Oncology Group Study 5592. J Clin Oncol. 2003 Apr 15; 21(8):1536-43.
    View PubMed
  50. Cella D, Eton DT, Lai JS, Peterman AH, Merkel DE. Combining anchor and distribution-based methods to derive minimal clinically important differences on the Functional Assessment of Cancer Therapy (FACT) anemia and fatigue scales. J Pain Symptom Manage. 2002 Dec; 24(6):547-61.
    View PubMed
  51. Eton DT, Lepore SJ. Prostate cancer and health-related quality of life: a review of the literature. Psychooncology. 2002 Jul-Aug; 11(4):307-26.
    View PubMed
  52. Cella D, Eton DT, Fairclough DL, Bonomi P, Heyes AE, Silberman C, Wolf MK, Johnson DH. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy-Lung (FACT-L) Questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol. 2002 Mar; 55(3):285-95.
    View PubMed
  53. Eton DT, Lepore SJ, Helgeson VS. Early quality of life in patients with localized prostate carcinoma: an examination of treatment-related, demographic, and psychosocial factors. Cancer. 2001 Sep 15; 92(6):1451-9.
    View PubMed
  54. Wiener RL, Eton D, Gibbons VP, Goldner JA, Johnson SH. A preliminary analysis of medical futility decisionmaking: law and professional attitudes. Behav Sci Law. 1998 Autumn; 16(4):497-508.
    View PubMed
  55. Eton DT, Gilner FH, Munz DC. The measurement of imagery vividness: A test of the reliability and validity of the Vividness of Visual Imagery Questionnaire and the Vividness of Movement Imagery Questionnaire Journal of Mental Imagery. 1998; 22:125-136.
  56. Johnson SH, Gibbons VP, Goldner JA, Wiener RL, Eton D. Legal and institutional policy responses to medical futility. J Health Hosp Law. 1997 Mar; 30(1):21-36.
    View PubMed